Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX to prevent postoperative pancreatic fistula after distal pancreatectomy (PROFIT)
2018-004239-63Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in pancreatic fistula (POPF), sponsored by Erasmus MC. Primary endpoints: Feasibility of preoperative endoscopic BOTOX injection into the sphincter of Oddi and Safety of preoperative endoscopic BOTOX injection into the sphincter of Oddi. Started Apr 2019; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on 2018-004239-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004239-63.